The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes

被引:12
|
作者
Savoia, Carmine [1 ]
Arrabito, Emanuele [1 ]
Parente, Rosa [1 ]
Sada, Lidia [1 ]
Madaro, Luca [2 ]
Nicoletti, Carmine [2 ]
Zezza, Luigi [1 ]
Alonzo, Alessandro [1 ]
Rubattu, Speranza [3 ]
Michelini, Serena [1 ]
Muller, Dominik N. [4 ]
Volpe, Massimo [1 ,3 ]
机构
[1] Univ Roma La Sapienza, StAndrea Hosp, Dept Clin & Mol Med, Div Cardiol, I-00185 Rome, Italy
[2] Univ Roma La Sapienza, DAHFMO Unit Histol & Med Embryol, I-00185 Rome, Italy
[3] IRCCS Neuromed, Pozzilli, IS, Italy
[4] Max Delbruck Ctr Mol Med, Berlin, Germany
关键词
nitric oxide; renin inhibition; reactive oxygen species (ROS); small artery; vascular remodelling; ENDOTHELIAL NITRIC-OXIDE;
D O I
10.1042/CS20120395
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
In the present study, we tested the hypothesis that chronic treatment with the direct rennin inhibitor aliskiren improves the remodelling of resistance arteries in dTGR (double-transgenic rats). dTGR (5 weeks) were treated with aliskiren (3 mg/kg of body mass per day) or ramipril (1 mg/kg of body mass per day) for 14 days and compared with age-matched vehicle-treated dTGR. BP (blood pressure) was similarly reduced in both aliskiren-treated and ramipril-treated rats compared with control dTGR (167 +/- 1 and 169 +/- 2 mmHg compared with 197 +/- 4 mmHg respectively; P<0.05). The M/L (media-to-lumen) ratio assessed on pressurized preparations was equally reduced in aliskiren-treated and ramipril-treated rats compared with controls (6.3 +/- 0.5 and 6.4 +/- 0.2% compared with 9.8 +/- 0.4% respectively; P<0.05). Endothelium-dependent and -independent relaxations were similar among the groups. L-NAME (N-G-nitrozL-arginine methyl ester) significantly reduced acetylcholine-induced dilation in drug-treated dTGR. This effect was significantly more prominent in aliskiren-treated rats. eNOS (endothelial NO synthase) expression showed a 2-fold increase only in aliskiren-treated dTGR as compared with controls (P<0.01) and ramipril-treated dTGR (P < 0.05). Plasma nitrite, as an index of NO production, was significantly increased in dTGR treated with either aliskiren or ramipril compared with controls. Only aliskiren induced a 2-fold increase in plasma nitrite, which was significantly greater than that induced by ramipril (P<0.05). gp91(Phox) expression and ROS (reactive oxygen species) production in aorta were significantly and similarly reduced by both drugs. In conclusion, equieffective hypotensive doses of aliskiren or rannipril reduced the M/L ratio of mesenteric arteries and improved oxidative stress in dTGR. However, only aliskiren increased further NO production in the vasculature. Hence, in dTGR, direct renin inhibition induces favourable effects similar to that induced by ACE (angiotensin-converting enzyme) inhibition in improving vascular remodelling through different mechanisms.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 50 条
  • [41] The development of the direct renin inhibitor aliskiren: treating hypertension and beyond
    Siragy, Helmy
    Huang, Jiqian
    Lieb, David C.
    EXPERT OPINION ON EMERGING DRUGS, 2008, 13 (03) : 417 - 430
  • [42] Successful Utilization of Aliskiren, a Direct Renin Inhibitor in Bartter Syndrome
    Bell, David S. H.
    SOUTHERN MEDICAL JOURNAL, 2009, 102 (04) : 413 - 415
  • [43] The direct renin inhibitor aliskiren localizes and persists in rat kidneys
    Feldman, David L.
    Jin, Liang
    Xuan, Hong
    Persohn, Elke
    Zhou, Wei
    Schuetz, Helmut
    Park, Joon-Keun
    Muller, Dominik N.
    Luft, Friedrich C.
    AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY, 2013, 305 (11) : F1593 - F1602
  • [44] Effectiveness of the Direct Renin Inhibitor, Aliskiren, in Patients With Resistant Hypertension
    Yoshitomi, Yuji
    Kawanishi, Ken-ichi
    Yamaguchi, Akihisa
    Sakurai, Shun-ichiro
    Minai, Kazuo
    Ishii, Toshikazu
    Tarutani, Yasuhiro
    Tsujibayashi, Takashi
    Kaneki, Masashi
    Saitou, Yuichi
    Suwa, Satoru
    INTERNATIONAL HEART JOURNAL, 2013, 54 (02) : 88 - 92
  • [45] TSUKUBA HYPERTENSIVE MICE TRANSGENIC MICE CARRYING BOTH HUMAN RENIN AND HUMAN ANGIOTENSINOGEN GENES
    MURAKAMI, K
    FUKAMIZU, A
    PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES, 1993, 69 (06): : 129 - 133
  • [46] Exaggeration of focal cerebral ischemia in transgenic mice carrying human renin and human angiotensinogen genes
    Inaba, Shinji
    Iwai, Masaru
    Tomono, Yumiko
    Kanno, Harumi
    Okayama, Hideki
    Mogi, Masaki
    Higaki, Jitsuo
    Horiuchi, Masatsugu
    HYPERTENSION, 2007, 50 (04) : E140 - E140
  • [47] Cardiovascular control in conscious transgenic mice carrying human renin and human angiotensinogen genes.
    Merrill, DC
    Carney, CL
    Granwehr, BP
    Schlager, G
    Robillard, JE
    Sigmund, CD
    FASEB JOURNAL, 1996, 10 (03): : 120 - 120
  • [48] Aliskiren: the first direct renin inhibitor available for clinical use
    Morganti, Alberto
    Lonati, Chiara
    JOURNAL OF NEPHROLOGY, 2011, 24 (05) : 541 - 549
  • [49] Exaggeration of Focal Cerebral Ischemia in Transgenic Mice Carrying Human Renin and Human Angiotensinogen Genes
    Inaba, Shinji
    Iwai, Masaru
    Tomono, Yumiko
    Senba, Izumi
    Furuno, Megumi
    Kanno, Harumi
    Okayama, Hideki
    Mogi, Masaki
    Higaki, Jitsuo
    Horiuchi, Masatsugu
    STROKE, 2009, 40 (02) : 597 - 603
  • [50] Aliskiren: First Direct Renin Inhibitor Approved for Clinical Use
    Morales Olivas, Francisco J.
    Estan Yago, Luis
    REVISTA ESPANOLA DE CARDIOLOGIA, 2009, : 41A - 48A